drugset / Trial / NCT00744211

Proteolytic Enzyme Induction Within the Human Myocardial Interstitium

NCT00744211

RandomizedParallel-groupDouble-blindOther

Summary

A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR) activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass (CPB). Increased ET-AR activation has been identified in patients with poor left ventricular (LV) function (reduced ejection fraction; EF). Accordingly, this study tested the hypothesis that a selective ET-AR antagonist (ET-ARA) administered peri-operatively would favorably affect post-CPB hemodynamic profiles in patients with a pre-existing poor LVEF.

Timeline

Start
2008-07
Primary completion
2011-06
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitaxentan Small molecule 1 mg/kg Intravenous
Subject Sitaxentan Small molecule 2 mg/kg Intravenous

Indications